Stocks Hit Session Lows; Biotech, Homebuilders Lead Slump
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
June New Home Sales Fall Well Short of Consesnus
July 24, 2015 10:00 AM EDT(Updated)
Sales of new single-family houses in June 2015 were at a seasonally adjusted annual rate of 482,000, said the U.S. Census Bureau and the Department of Housing and Urban Development. Data came in below the consensus of 548,000 and 6.8%... More
Biogen (BIIB) Tops Q2 EPS by 12c; Cuts FY15 Revenue Growth, EPS Outlook
July 24, 2015 6:50 AM EDT(Updated - July 24, 2015 6:51 AM EDT)
Biogen (Nasdaq: BIIB) reported Q2 adjusted EPS of $4.22, which was $0.12 better than the analyst estimate of $4.10. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.71 billion.
Neurology Highlights
In April 2015, the U.S. Food and Drug Administration accepted for review the Biologics License Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis. ZINBRYTA is being jointly developed by Biogen and... More